DOCK4 and prostate carcinoma: It suppresses the invasion and migration of prostate cancer cells by targeting DOCK4. Proteasome inhibitor bortezomib leads to insufficient inhibition on cell invasion due to miR-33b-3p downregulation, which can be overcome by overexpression of miR-33b-3p in prostate cancer.